ABT-239 is an H₃-receptor inverse agonist developed by Abbott. It has stimulant and

nootropic Nootropics ( , or ) (colloquial: smart drugs and cognitive enhancers, similar to adaptogens) are a wide range of natural or synthetic dietary supplement, supplements or drugs and other substances that are claimed to improve cognitive function ...

effects, and has been investigated as a treatment for ADHD, Alzheimer's disease, and

schizophrenia Schizophrenia is a mental disorder characterized by continuous or relapsing episodes of psychosis. Major symptoms include hallucinations (typically hearing voices), delusions, and disorganized thinking. Other symptoms include social wit ...

. ABT-239 is more active at the human H₃ receptor than comparable agents such as thioperamide, ciproxifan, and

cipralisant Cipralisant (GT-2331, tentative trade name Perceptin) is an extremely potent histamine H3 receptor ligand originally developed by Gliatech. Cipralisant was initially classified as a selective H3 antagonist, but newer research (2005) suggests a ...

. It was ultimately dropped from human trials after showing the dangerous cardiac side effect of

QT prolongation Long QT syndrome (LQTS) is a condition affecting repolarization (relaxing) of the heart after a heartbeat, giving rise to an abnormally lengthy QT interval. It results in an increased risk of an irregular heartbeat which can result in fainting ...

, but is still widely used in animal research into H₃ antagonists / inverse agonists.

References

External links

* Nootropics H3 receptor antagonists Benzonitriles Benzofuranethanamines Pyrrolidines Biphenyls {{nervous-system-drug-stub